Clarissa Sowemimo-Coker
Algemeen Directeur bij OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC
Vermogen: 11 275 $ op 30-04-2024
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Indraneil Mahapatra | M | 44 |
Oxford Cannabinoid Technologies Ltd.
 Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | 7 jaar |
| Charanjit Dhillon | F | 66 |
Oxford Cannabinoid Technologies Ltd.
Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | - |
| Julie Pomeroy | F | 69 | - | |
| Timothy Corn | M | 73 | 1 jaar | |
| Karen Lowe | F | 55 |
Oxford Cannabinoid Technologies Ltd.
Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | - |
| John Lucas | M | 58 |
Oxford Cannabinoid Technologies Ltd.
Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | 3 jaar |
| Paul Smalley | M | - | 2 jaar | |
| Robin Bennett | M | - | 2 jaar | |
| Richard Hathaway | M | 57 |
Oxford Cannabinoid Technologies Ltd.
Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | - |
| Bishrut Mukherjee | M | 37 |
Oxford Cannabinoid Technologies Ltd.
Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | - |
| Valentino Parravicini | M | 55 | 4 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Hee-Dong Kim | M | - |
Oxford Cannabinoid Technologies Ltd.
Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | 4 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigd Koninkrijk | 12 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Clarissa Sowemimo-Coker
- Persoonlijk netwerk
